Last reviewed · How we verify
Optive®
Optive is an artificial tear solution that lubricates and protects the ocular surface to relieve symptoms of dry eye disease.
Optive is an artificial tear solution that lubricates and protects the ocular surface to relieve symptoms of dry eye disease. Used for Dry eye disease / Keratoconjunctivitis sicca.
At a glance
| Generic name | Optive® |
|---|---|
| Sponsor | Laboratorios Sophia S.A de C.V. |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Optive combines multiple lubricating agents including carboxymethylcellulose and glycerin to provide sustained moisture and protection to the cornea and conjunctiva. The formulation mimics natural tears and helps restore the tear film, reducing irritation, grittiness, and discomfort associated with dry eye syndrome. It also contains electrolytes to maintain osmotic balance and support ocular surface health.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Transient blurred vision
- Eye irritation
- Mild ocular discomfort
Key clinical trials
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease (PHASE3)
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® (PHASE1)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
- Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops (NA)
- Optive Brand For Day And Night Dry Eye Management (NA)
- Clinical Outcomes Following Treatment With SYSTANE® BALANCE (NA)
- A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye (PHASE4)
- Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optive® CI brief — competitive landscape report
- Optive® updates RSS · CI watch RSS
- Laboratorios Sophia S.A de C.V. portfolio CI